Developer docs
API playgroundTry for free, no card

Search company profiles

Elevian

Full company profile

uuid0000xrb

Namestring
Elevian
Legal namestring
Elevian, Inc.
Websiteurl
elevian.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Elevian is a privately held, clinical-stage biotechnology company developing recombinant protein therapeutics based on Growth Differentiation Factor 11 (GDF11), a circulating blood factor that declines with age. Founded in 2018 by Harvard Stem Cell Institute scientists (Lee Rubin, Amy Wagers, Rich Lee, Ryan Walker) alongside serial biotech entrepreneurs Mark Allen (CEO) and Sebastian Giwa (Chairman), the company is headquartered in Allston, Massachusetts. Its lead program, rGDF11, is a recombinant protein shown in preclinical models to facilitate motor function recovery in both ischemic and hemorrhagic stroke by promoting neovascularization, neurogenesis, and reducing inflammation, with a therapeutic window extending into hours-to-days post-stroke, in contrast to existing neuroprotective therapies that must be administered within the first few hours.

The company's broader pipeline leverages rGDF11 and additional GDF11 pathway modulators to address cardiovascular, metabolic (obesity, Type II diabetes), pulmonary, renal, inflammatory, and skeletal muscle dysfunction. Elevian has secured exclusive worldwide rights to a portfolio of granted patents covering GDF11 polypeptide compositions and their therapeutic uses, and has developed a scalable, high-producing rGDF11 cell line and purification process for IND-enabling and early clinical studies. The company is pre-revenue with no commercial products; its business model is the standard clinical-stage biotech path of advancing therapeutics through regulatory approval and ultimately to pharmaceutical product sales or licensing partnerships, supported by clinical trial site engagement with hospitals and rehabilitation centers.

Short descriptiontext

Elevian is a clinical-stage biotech developing recombinant GDF11 (rGDF11) protein therapeutics, with a lead program targeting stroke recovery and a broader pipeline for age-related diseases including cardiovascular, metabolic, and neuromuscular disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNewton, United States
HQ citystring
Newton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine therapeutics, stroke recovery treatment, recombinant protein drugs, anti-aging biotechnology, age-related disease therapies
Industry3 codes
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Therapeutics
TypeOne Time License
Description

As a pre-revenue biotech company, Elevian does not currently generate revenue. The company is developing rGDF11 and GDF11 pathway modulators as therapeutic candidates targeting stroke recovery and age-related diseases. Future revenue will come from pharmaceutical product sales following regulatory approval.

elevian.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Elevian develops a pipeline of regenerative medicines centered on recombinant Growth Differentiation Factor 11 (rGDF11), a protein therapeutic that has demonstrated in preclinical models the ability to promote recovery from stroke and treat age-related diseases. The lead program targets post-stroke recovery by promoting neovascularization, neurogenesis, and reducing inflammation. Additional programs utilize rGDF11 and other GDF11 pathway modulators for cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • rGDF11 improves limb and core body motor function measures (forelimb placement, hindlimb placement, and elevated body swing) in rat permanent MCAO model of ischemic stroke when dosing initiated within 24 hours or up to several days post stroke
+2 more records
Product overview1 text field

Elevian is developing a pipeline of regenerative medicines centered on rGDF11 (recombinant Growth Differentiation Factor 11) and other GDF11 pathway modulators. The lead product rGDF11 is a recombinant protein therapeutic in preclinical/IND-enabling stages for stroke recovery, with potential applications across multiple age-related diseases. The company's therapeutic approach focuses on restoring youthful regenerative capacity by targeting the GDF11 pathway, which declines with age.

Product and service2 records
1rGDF11 (recombinant Growth Differentiation Factor 11)
CategoryRecombinant protein therapeutic
Description

Recombinant protein therapeutic developed for treatment of stroke in the hours and days following the event; in preclinical animal models, has facilitated recovery of motor function in ischemic and hemorrhagic stroke by promoting neovascularization, stimulating neurogenesis, and reducing inflammation. Being advanced toward IND-enabling studies and Phase 1 clinical trials.

2GDF11 Pathway Modulators
CategoryRegenerative medicine pipeline
Description

Pipeline of therapeutic programs utilizing rGDF11 and other modulators of the GDF11 pathway for the treatment of multiple aging-associated diseases including cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction. Targets improvements in glucose metabolism, insulin response, insulin sensitivity, weight loss, and tissue regeneration across multiple organ systems.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2019-01-09
Description

Elevian entered a research collaboration with Insilico Medicine to discover drugs that target aging using state-of-the-art AI-enabled drug discovery techniques. The partnership leverages Insilico's AI platform to identify and develop GDF11 pathway modulators.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Elevian's research is sponsored at Harvard Stem Cell Institute laboratories, with scientific co-founders Lee Rubin, Amy Wagers, Rich Lee, and Ryan Walker leading research on rGDF11 pharmacokinetics, cardiovascular preclinical models, neurodegenerative models, and protein engineering.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Athersys
TypeDirect peer
Description

Clinical-stage cell therapy company developing MultiStem for ischemic stroke and other conditions — the closest direct competitor to Elevian in regenerative stroke therapy, with a similar late-preclinical/early-clinical profile.

TypeDirect peer
Description

Cell therapy company developing SB623 (modified allogeneic mesenchymal stem cells) for chronic stroke recovery — directly comparable regenerative medicine approach for the same post-stroke indication.

TypeDirect peer
Description

UK-based clinical-stage cell therapy company with a CTX stem cell line for stroke disability — directly comparable in indication and regenerative mechanism.

TypeBroad incumbent
Description

Commercial-stage cell therapy company with mesenchymal stem cell platforms in inflammatory and cardiovascular diseases — broader incumbent with overlapping regenerative biology and relevant industry context (Elevian SVP Tony Sandrasagra was previously VP R&D there).

TypeDirect peer
Description

Clinical-stage biotechnology company developing senolytic therapeutics to address aging-related diseases — directly comparable mission of treating age-driven degeneration, though with a small-molecule senolytic rather than a regenerative protein approach.

TypeEmerging player
Description

AI-driven drug discovery company focused on aging and age-related diseases — overlapping longevity mission and an existing Elevian research collaborator, providing pipeline expansion leverage.

TypeBroad incumbent
Description

Alphabet-backed R&D company focused on aging and age-related diseases — a well-funded, broadly positioned incumbent in the longevity/regenerative medicine space with overlapping scientific ambition.

TypeBroad incumbent
Description

Well-capitalized (>$3B raised) biotech focused on cellular reprogramming to reverse disease, injury, and age-related conditions — directly overlapping mission of restoring youthful regenerative capacity.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic cell transplants for CNS and other indications — comparable regenerative medicine platform targeting central nervous system repair.

10BioTime (Lineage)
TypeDirect peer
Description

Regenerative medicine company developing cell-based therapies across multiple age-related disease areas — directly comparable in regenerative medicine orientation, though now operating primarily through Lineage Cell Therapeutics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles25 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elevian

Regenerative Medicine Biopharmaceuticalselevian.com

Elevian is a clinical-stage biotech developing recombinant GDF11 (rGDF11) protein therapeutics, with a lead program targeting stroke recovery and a broader pipeline for age-related diseases including cardiovascular, metabolic, and neuromuscular disorders.

What Elevian does

Elevian is a privately held, clinical-stage biotechnology company developing recombinant protein therapeutics based on Growth Differentiation Factor 11 (GDF11), a circulating blood factor that declines with age. Founded in 2018 by Harvard Stem Cell Institute scientists (Lee Rubin, Amy Wagers, Rich Lee, Ryan Walker) alongside serial biotech entrepreneurs Mark Allen (CEO) and Sebastian Giwa (Chairman), the company is headquartered in Allston, Massachusetts. Its lead program, rGDF11, is a recombinant protein shown in preclinical models to facilitate motor function recovery in both ischemic and hemorrhagic stroke by promoting neovascularization, neurogenesis, and reducing inflammation, with a therapeutic window extending into hours-to-days post-stroke, in contrast to existing neuroprotective therapies that must be administered within the first few hours.

The company's broader pipeline leverages rGDF11 and additional GDF11 pathway modulators to address cardiovascular, metabolic (obesity, Type II diabetes), pulmonary, renal, inflammatory, and skeletal muscle dysfunction. Elevian has secured exclusive worldwide rights to a portfolio of granted patents covering GDF11 polypeptide compositions and their therapeutic uses, and has developed a scalable, high-producing rGDF11 cell line and purification process for IND-enabling and early clinical studies. The company is pre-revenue with no commercial products; its business model is the standard clinical-stage biotech path of advancing therapeutics through regulatory approval and ultimately to pharmaceutical product sales or licensing partnerships, supported by clinical trial site engagement with hospitals and rehabilitation centers.

Elevian firmographics

Firmographics
Name
Elevian
Legal name
Elevian, Inc.
Website
https://elevian.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Elevian is a clinical-stage biotech developing recombinant GDF11 (rGDF11) protein therapeutics, with a lead program targeting stroke recovery and a broader pipeline for age-related diseases including cardiovascular, metabolic, and neuromuscular disorders.
Ownership category
akta.pro rank

Elevian industry classification

Industry
Product category
Regenerative Medicine Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine therapeutics
  • Stroke recovery treatment
  • Recombinant protein drugs
  • Anti-aging biotechnology
  • Age-related disease therapies

Where Elevian is headquartered

Location

Headquarters

HQ city
Newton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Elevian business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Therapeutics: As a pre-revenue biotech company, Elevian does not currently generate revenue. The company is developing rGDF11 and GDF11 pathway modulators as therapeutic candidates targeting stroke recovery and age-related diseases. Future revenue will come from pharmaceutical product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Elevian product offering

Product offering

Core offering

Elevian develops a pipeline of regenerative medicines centered on recombinant Growth Differentiation Factor 11 (rGDF11), a protein therapeutic that has demonstrated in preclinical models the ability to promote recovery from stroke and treat age-related diseases. The lead program targets post-stroke recovery by promoting neovascularization, neurogenesis, and reducing inflammation. Additional programs utilize rGDF11 and other GDF11 pathway modulators for cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.

Product overview

Elevian is developing a pipeline of regenerative medicines centered on rGDF11 (recombinant Growth Differentiation Factor 11) and other GDF11 pathway modulators. The lead product rGDF11 is a recombinant protein therapeutic in preclinical/IND-enabling stages for stroke recovery, with potential applications across multiple age-related diseases. The company's therapeutic approach focuses on restoring youthful regenerative capacity by targeting the GDF11 pathway, which declines with age.

Differentiator

Problem solved

Functional benefit

Products and services

  • rGDF11 (recombinant Growth Differentiation Factor 11) Recombinant protein therapeutic developed for treatment of stroke in the hours and days following the event; in preclinical animal models, has facilitated recovery of motor function in ischemic and hemorrhagic stroke by promoting neovascularization, stimulating neurogenesis, and reducing inflammation. Being advanced toward IND-enabling studies and Phase 1 clinical trials.
  • GDF11 Pathway Modulators Pipeline of therapeutic programs utilizing rGDF11 and other modulators of the GDF11 pathway for the treatment of multiple aging-associated diseases including cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction. Targets improvements in glucose metabolism, insulin response, insulin sensitivity, weight loss, and tissue regeneration across multiple organ systems.

Quantifiable outcome

  • rGDF11 improves limb and core body motor function measures (forelimb placement, hindlimb placement, and elevated body swing) in rat permanent MCAO model of ischemic stroke when dosing initiated within 24 hours or up to several days post stroke
  • +2 more outcomes

Companies that use Elevian

Customer profile

Segments2 records

Ideal customer profiles1 record

Elevian technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Elevian partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered strategic and core.

  • Insilico MedicinestrategicTechnology or Integration · 9 January 2019Elevian entered a research collaboration with Insilico Medicine to discover drugs that target aging using state-of-the-art AI-enabled drug discovery techniques. The partnership leverages Insilico's AI platform to identify and develop GDF11 pathway modulators.
  • Harvard Stem Cell InstitutecoreStrategic or Co-development PartnerElevian's research is sponsored at Harvard Stem Cell Institute laboratories, with scientific co-founders Lee Rubin, Amy Wagers, Rich Lee, and Ryan Walker leading research on rGDF11 pharmacokinetics, cardiovascular preclinical models, neurodegenerative models, and protein engineering.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Elevian competitors and assessment

Company assessment

Direct peers

  • Athersys: Clinical-stage cell therapy company developing MultiStem for ischemic stroke and other conditions — the closest direct competitor to Elevian in regenerative stroke therapy, with a similar late-preclinical/early-clinical profile.
  • SanBio: Cell therapy company developing SB623 (modified allogeneic mesenchymal stem cells) for chronic stroke recovery — directly comparable regenerative medicine approach for the same post-stroke indication.
  • ReNeuron: UK-based clinical-stage cell therapy company with a CTX stem cell line for stroke disability — directly comparable in indication and regenerative mechanism.
  • Unity Biotechnology: Clinical-stage biotechnology company developing senolytic therapeutics to address aging-related diseases — directly comparable mission of treating age-driven degeneration, though with a small-molecule senolytic rather than a regenerative protein approach.
  • Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplants for CNS and other indications — comparable regenerative medicine platform targeting central nervous system repair.
  • BioTime (Lineage): Regenerative medicine company developing cell-based therapies across multiple age-related disease areas — directly comparable in regenerative medicine orientation, though now operating primarily through Lineage Cell Therapeutics.

Broad incumbents

  • Mesoblast: Commercial-stage cell therapy company with mesenchymal stem cell platforms in inflammatory and cardiovascular diseases — broader incumbent with overlapping regenerative biology and relevant industry context (Elevian SVP Tony Sandrasagra was previously VP R&D there).
  • Calico Life Sciences: Alphabet-backed R&D company focused on aging and age-related diseases — a well-funded, broadly positioned incumbent in the longevity/regenerative medicine space with overlapping scientific ambition.
  • Altos Labs: Well-capitalized (>$3B raised) biotech focused on cellular reprogramming to reverse disease, injury, and age-related conditions — directly overlapping mission of restoring youthful regenerative capacity.

Emerging players

  • Insilico Medicine: AI-driven drug discovery company focused on aging and age-related diseases — overlapping longevity mission and an existing Elevian research collaborator, providing pipeline expansion leverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Elevian social profiles

Digital presence

Elevian financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elevian leadership team

Management profile

Number of profiles

Profiles25 records

Elevian funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elevian M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elevian

What does Elevian do?

Elevian develops a pipeline of regenerative medicines centered on recombinant Growth Differentiation Factor 11 (rGDF11), a protein therapeutic that has demonstrated in preclinical models the ability to promote recovery from stroke and treat age-related diseases. The lead program targets post-stroke recovery by promoting neovascularization, neurogenesis, and reducing inflammation. Additional programs utilize rGDF11 and other GDF11 pathway modulators for cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.

Is Elevian a public or private company?

Elevian is a private company. It is classified as venture growth investor backed and is currently operating.

When was Elevian founded?

Elevian was founded in 2018. It employs 1 to 10 people.

Where is Elevian based?

Elevian is headquartered in Newton, United States, in the North America region.

How does Elevian make money?

One revenue line is on record: pharmaceutical Therapeutics.

Who are Elevian's main competitors?

Direct peers on record are Athersys, SanBio, ReNeuron, Unity Biotechnology, Lineage Cell Therapeutics and BioTime (Lineage). Broad incumbents are Mesoblast, Calico Life Sciences and Altos Labs. Insilico Medicine is listed as an emerging player.

Does Elevian have an API?

No public API is recorded for Elevian.

What industry is Elevian in?

Elevian's product category is Regenerative Medicine Biopharmaceuticals. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics), with a secondary code of HLAAAGAI, Neural & Spinal Cord Regeneration. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comDiabetes Pipeline Insights Report 2024 (Updated) | Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Novo Nordisk, Enthera, andDelveInsight's Diabetes Pipeline Insights 2024 report profiles over 200 companies and 200+ pipeline drugs for diabetes treatment, covering clinical trials and nonclinical products. It highlights leading companies like Daewoong, Janssen, and Novo Nordisk, and notes Phase III trials for ertugliflozin in pediatric T2D and Omada's CGM study.AvInvesting in Longevity TechThis article from Alumni Ventures provides an educational overview of the longevity technology sector, covering its four main pillars (prevention, diagnostics, treatment, and renewal) and emerging applications including gene therapy, age tech, senolytic drug therapy, AI, and biohacking. The longevity sector attracted $5.2 billion across 130 deals in 2022, with the most notable being a $3 billion investment into Altos Labs, though 2023 investment has faced headwinds from macroeconomic conditions. The article profiles several longevity startups including Bionic Health (AI health platform raising $3M seed), Elevian (stroke treatment biotech valued at $100M with $60M+ raised), Sunbird Bio (Alzheimer's diagnostic developer post-merger), and Retro Biosciences (gene therapy startup backed by Sam Altman's $180 million investment).The New York TimesCan a ‘Magic’ Protein Slow the Aging Process?Elevian is researching GDF11, a protein that rejuvenates heart and skeletal muscle tissue in mice, as discovered by Harvard Stem Cell Institute scientists. The protein also stimulated new blood vessels and neurons in the brain, and may help treat age-related conditions like strokes.Grit Daily NewsBiotech Startup Elevian Closes $40 mln Series A RoundMassachusetts-based biotech startup Elevian has closed a $40 million oversubscribed Series A round led by Prime Movers Lab, with participation from Bold Capital, Leslie Ventures and the John A Kuelbs Family Office, bringing total funding to over $64 million. The company plans to submit a new drug application, expand manufacturing and complete Phase 1 trials for stroke recovery.SecSEC FORM DElevian, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates a total offering amount of approximately $42.7 million, with over $22.7 million already sold to 29 investors as of August 11, 2021. The company is based in Miami Beach, Florida.VC News DailyElevian Raises $40M Series AElevian, an emerging biotech company, has raised $40 million in an oversubscribed Series A funding round led by Prime Movers Lab. The funding will support Elevian's development of medicines aimed at restoring youthful regenerative capacity and potentially treating multiple age-related diseases. This investment reflects growing interest in biotech solutions focused on aging and regenerative health.FierceBiotechElevian snags $40M for stroke recovery and age-related diseasesMassachusetts biotech Elevian has raised $40 million in Series A funding to advance its lead drug candidate, targeting stroke recovery based on research into the GDF11 protein. The company plans to initiate phase 1 trials in early 2023, aiming for a fast-tracked regulatory pathway due to the unmet medical need and short clinical endpoints.PR NewswireElevian Raises $40 Million Series A to Advance Treatments for Stroke Recovery and Age-Related DiseasesBiotech company Elevian announced the closing of a $40 million Series A funding round led by Prime Movers Lab to advance its research on age-related diseases. The capital will be used to submit an investigational new drug application, scale manufacturing, and complete Phase 1 clinical trials for its lead candidate targeting stroke recovery.PR NewswireElevian Adds Stroke Clinical Advisory TeamElevian, an emerging biotech company, announced the formation of a stroke clinical advisory team to guide the development of its drug rGDF11 for post-stroke recovery. The team comprises leading experts from institutions such as Massachusetts General Hospital, UCLA, and Duke University. This strategic move aims to advance the clinical translation of preclinical data showing that rGDF11 promotes motor function recovery.FinSMEsElevian Raises $15M in Equity FundingElevian, an Allston, MA-based biotech, closed a $15M equity financing led by Prime Movers Lab. The funds will advance recombinant GDF11 toward clinical trials for stroke and other age-related diseases. The company also appointed two board members and expanded its leadership team.